Latest Oncology Stories
DUBLIN, June 17, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/w4l9nk/drug_delivery_in) has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies [http://www.researchandmarkets.com/research/w4l9nk/drug_delivery_in ]" to their offering. Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed...
- Pooled Analysis from Four Phase 1 and Phase 2 Clinical Studies Demonstrates Persistence of Treatment - SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from a pooled analysis of data from completed Phase 1 and 2 studies of pacritinib, an oral JAK2/FLT3 inhibitor, demonstrating the safety and tolerability profile of pacritinib in patients with myelofibrosis. An integrated safety analysis of four completed Phase 1...
- Results Presented at 18th Congress of the European Hematology Association - SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from sub-set analyses of data from the Phase 3 EXTEND, or PIX301, clinical trial of PIXUVRI(®) (pixantrone). The analyses evaluated the efficacy of PIXUVRI in the subset of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), as confirmed by central independent...
SUNNYVALE, Calif., June 16, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL). Pharmacyclics sponsored both studies and is jointly developing ibrutinib with Janssen...
Data presented at the European Hematology Association (EHA) Annual Congress RARITAN, N.J., June 16, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen), today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, shows efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma (DLBCL). The studies...
Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, commends family for remaining positive and supporting each other despite three different cancer diagnoses in the past 16 years. New York, NY (PRWEB) June 15, 2013 On June 15, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, commends a family for remaining positive and continuously supporting each other despite receiving three different cancer diagnoses...
If Debris Could Contain Asbestos, Leave It for Pros, Say Mesothelioma Lawyers at Baron and Budd. DALLAS (PRWEB) June 15, 2013 The mesothelioma attorneys at Baron and Budd are advocating for awareness of potential asbestos in construction materials after an onslaught of tornadoes in Oklahoma. Cleanup has begun in Moore, Oklahoma, after a mile-wide EF-5 tornado struck the small town on May 20, killing 24. This was followed by another tornado on May 31, causing ten more deaths in a similar...
The Lung Cancer Asbestos Victims Center says, "We are doing everything possible to make certain every diagnosed victim of mesothelioma, or any type of lung cancer, who was exposed to asbestos in a shipyard has instant access to the nation's leading mesothelioma, or asbestos exposure compensation lawyers, because these extremely skilled legal specialists consistently get the best financial compensation results for their clients." For more information diagnosed victims of...
Published in the Journal for ImmunoTherapy of Cancer, review offers recommendations for manufacturing, pre-clinical studies, and clinical trial designs of cancer immunotherapies Milwaukee, WI (PRWEB) June 14, 2013 A picture of what the FDA is looking for in cancer immunotherapy product development appears in an extensive review article published in the inaugural issue of the Journal for ImmunoTherapy of Cancer. This review outlines a series of recommendations from the FDA, including cited...
Two locals, Manny Camara and Karen Routt have been named the winners of this year’s Silicon Valley Man & Woman of the Year for The Leukemia & Lymphoma Society’s (LLS) – Greater Bay Area Chapter. San Jose, CA (PRWEB) June 13, 2013 Manny Camara and Karen Routt have been named as this year’s Silicon Valley Man & Woman of the Year for The Leukemia & Lymphoma Society’s (LLS)—Greater Bay Area Chapter. During a spirited ten-week cancer fundraising period beginning...
